<DOC>
	<DOCNO>NCT01521832</DOCNO>
	<brief_summary>This trial healthy volunteer study safety , tolerability pharmacokinetics single multiple escalate dos SEN0014196 .</brief_summary>
	<brief_title>Escalating Dose Study Healthy Volunteers With SEN0014196</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Subjects Groups A G Groups I K males ethnic origin 18 55 year age body mass index ( BMI ) 18 31 kg/m2 inclusive . Subjects Groups H L females ethnic origin 18 65 year age body mass index ( BMI ) 18 31 kg/m2 inclusive . All subject body weight great 50 kg . For Group H , woman nonchildbearing potential , defined follow : Female subject 50 year age less must surgically sterile postmenopausal ( define least two year post cessation menses and/or follicular stimulate hormone &gt; 18 mIU/mL serum oestradiol &lt; 110 pmol/L ) , nonlactating negative serum pregnancy test Female subject 51 year age must surgically sterile postmenopausal ( define value follicular stimulate hormone &gt; 18 mIU/mL spontaneous menstruation least one year first dose ) , nonlactating negative serum pregnancy test . Subjects must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation Note : congenital nonhaemolytic hyperbilirubinaemia acceptable serum potassium must within normal reference range ( confirmed repeat analysis ) . Subjects give write informed consent participate study abide study restriction . Male subject Female subject Group H , whose partner willing use appropriate contraception ( condom ) spermicidal foam/gel/film/cream/suppository ) time first dose 3 month final dosing occasion . Female subject Group L , willing use appropriate contraception ( condom ) spermicidal foam/gel/film/cream/suppository ) time screen 3 month final dosing occasion , menstrual period 28 day first dose . Subjects receive prescribed systemic topical medication within 14 day first dose administration ( female subject , stable hormone replacement therapy acceptable ) unless opinion Investigator medication interfere study procedure compromise safety . Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day first dose administration ( exception vitamin/mineral supplement ) unless opinion Investigator medication interfere study procedure compromise safety . Subjects received medication , include St John 's Wort , know chronically alter drug absorption elimination process within 30 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety Subjects still participate clinical study ( e.g . attend followup visit ) participate clinical study involve administration investigational drug ( new chemical entity ) past 3 month , possible confirm use The Over Volunteering Protection Service ( TOPS ) . Subjects donate blood , plasma platelet 2 month prior screen make donation two occasion within 12 month precede first dose administration . Subjects significant history drug allergy determine Investigator . Subjects clinically significant allergic disease ( exclude nonactive hayfever ) determine Investigator . Subjects supine blood pressure supine pulse rate high 140/90 mmHg 100 beat per minute ( bpm ) , respectively , low 90/50 mmHg 40 bpm , respectively , confirm repeat assessment . Subjects consume 28 unit ( male ) 21 unit ( female ) alcohol per week significant history alcoholism drug/chemical abuse determine Investigator ( one unit alcohol equal ½ pint [ 285 mL ] beer lager , one glass [ 125 mL ] wine , 1/6 gill [ 25 mL ] spirit ) . Subjects positive urine drug screen alcohol breath test result screen first admission . Or history substance abuse last 12 month prior start study . Subjects smoke 5 cigarette equivalent tobacco per day . Subjects , history , clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , haematological major disorder determine Investigator . Subjects , family history Huntington 's Disease Subjects previously receive histone deacetylase inhibitor e.g . vorinostat ( Zolinza® ) participate clinical trial use histone deacetylase inhibitor . Subjects clinically significant illness within 4 week start dose administration determine Investigator Subjects know serum hepatitis , carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody , positive result test HIV antibody . Subjects abnormality 12lead ECG , opinion investigator , increase risk participate study , QTcF interval &gt; 450 msec ( male ) great 470msec ( female ) , sinus rhythm PR interval &lt; 110 msec &gt; 240 msec , confirm repeat ECG . Subjects , opinion Investigator , participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>